BRPI0915255A2 - célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica - Google Patents

célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica

Info

Publication number
BRPI0915255A2
BRPI0915255A2 BRPI0915255A BRPI0915255A BRPI0915255A2 BR PI0915255 A2 BRPI0915255 A2 BR PI0915255A2 BR PI0915255 A BRPI0915255 A BR PI0915255A BR PI0915255 A BRPI0915255 A BR PI0915255A BR PI0915255 A2 BRPI0915255 A2 BR PI0915255A2
Authority
BR
Brazil
Prior art keywords
cell
foxp3
individual
natural killer
killer
Prior art date
Application number
BRPI0915255A
Other languages
English (en)
Portuguese (pt)
Inventor
Ricardo Simões Da Silva Graça Luis
Sofia Ferreira Monteiro Marta
Original Assignee
Inst De Medicina Molecular
Univ De Lisboa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Medicina Molecular, Univ De Lisboa filed Critical Inst De Medicina Molecular
Publication of BRPI0915255A2 publication Critical patent/BRPI0915255A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0915255A 2008-11-13 2009-11-13 célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica BRPI0915255A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11436208P 2008-11-13 2008-11-13
PT10476409 2009-09-25
PCT/PT2009/000060 WO2010056144A2 (en) 2008-11-13 2009-11-13 Foxp3+ natural kiler t-cells and the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
BRPI0915255A2 true BRPI0915255A2 (pt) 2018-02-06

Family

ID=42138978

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915255A BRPI0915255A2 (pt) 2008-11-13 2009-11-13 célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica

Country Status (8)

Country Link
US (1) US20120114675A1 (https=)
EP (1) EP2356222A2 (https=)
JP (1) JP2012508575A (https=)
CN (1) CN102216448A (https=)
AU (1) AU2009314704A1 (https=)
BR (1) BRPI0915255A2 (https=)
CA (1) CA2743502A1 (https=)
WO (1) WO2010056144A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603892B (zh) * 2012-02-22 2013-10-30 尉军 一种肿瘤标志物foxp3抗原多肽及应用
AU2015228372B2 (en) * 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015273501B2 (en) * 2014-06-11 2021-01-21 Polybiocept Gmbh Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN105039255A (zh) * 2015-09-09 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种nkt细胞诱导培养的添加剂及诱导培养的方法
CN107475194B (zh) * 2017-10-09 2018-07-24 天津长和生物技术有限公司 Nkt细胞培养基、培养方法及二者的应用
US20220184172A1 (en) * 2019-04-19 2022-06-16 The Regents Of The University Of California Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2025221808A1 (en) * 2024-04-15 2025-10-23 Trustees Of Tufts College Efficient epigenetic reprogramming of t effector cells into stable regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
DE60141510D1 (de) * 2000-04-11 2010-04-22 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf-beta zur induktion von t-suppressorzellen
JP4989850B2 (ja) * 2002-10-25 2012-08-01 アメリカ合衆国 ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法

Also Published As

Publication number Publication date
CN102216448A (zh) 2011-10-12
WO2010056144A2 (en) 2010-05-20
JP2012508575A (ja) 2012-04-12
AU2009314704A1 (en) 2010-05-20
WO2010056144A3 (en) 2010-07-22
US20120114675A1 (en) 2012-05-10
CA2743502A1 (en) 2010-05-20
EP2356222A2 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
BRPI0915255A2 (pt) célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
EP3904502A3 (en) Compositions and methods
WO2009086504A3 (en) Collagen formulations for improved skin care
EP3587558A3 (en) Methods of populating a gastrointestinal tract
BRPI0909610A2 (pt) "mab de igg1 humano, purificado que se liga especificamente a il-1a humano, conjunto de ácidos nucleicos isolados, método para matar uma célula que expressa il-1a humano, método de inibição da migração de uma célula através de uma matriz de membrana basal, método de inibição de um aumento induzido por il-1a na expressão de e-selectina sobre a superfície de uma célula endotelial humana e método de rastreamento de inflamações em pacientes humanos"
MX2009011316A (es) Derivados del acido lipoico.
EP2337846A4 (en) NON-NATURAL AMINO ACID-REPLICATION-DEPENDENT MICRO-ORGANISMS AND VACCINES
BR112013019628A2 (pt) conjugados de polímero-carboidrato-lipídeo
WO2010065876A3 (en) Methods and compositions related to th-1 dendritic cells
IL199005A0 (en) Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
EP2364084A4 (en) PHARMACEUTICAL COMPOSITIONS WITH LIPONIC ACID IN LOW DOSAGE AND METHOD
EP3252068A3 (en) Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
ATE547110T1 (de) Verwendung von zellen aus fettgewebe zur herstellung eines antitumoralen medikaments
BRPI0820960B8 (pt) composição, composição farmacêutica, e uso da composição
EP2222693A4 (en) MUTANTS OF LYSINDECARBOXYLASE, VACCINES AGAINST PERIODONTITIS AND METHOD OF USE
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2010109180A8 (en) Composition for the administration of polymeric drugs
FR2917087B1 (fr) Nouveaux 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique.
IT1391032B1 (it) Biomassa arricchita in rame, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa
WO2011078695A3 (en) Acoustically sensitive drug delivery particles comprising low concentrations of phosphatidylethanolamine
FR2917089B1 (fr) Nouveaux 4-heteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique.
AR056499A1 (es) Compuestos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]